| Literature DB >> 30581316 |
Usman Sayeed1, Gulshan Wadhwa2, Qazi Mohd Sajid Jamal3, Mohammad A Kamal4,5, Salman Akhtar6, Mohd Haris Siddiqui6, M Salman Khan1.
Abstract
Japanese encephalitis (JE), a viral disease has seen a drastic and fatal enlargement in the northern states of India in the current decade. The better and exact cure for the disease is still in waiting. For the cause an in silico strategy in the development of the peptide vaccine has been taken here for the study. A computational approach to find out the Major Histocompatibility Complex (MHC) binding peptide has been implemented. The prediction analysis identified MHC class I (using propred I) and MHC class II (using propred) binding peptides at an expectable percent predicted IC (50) threshold values. These predicted Human leukocyte antigen [HLA] allele binding peptides were further analyzed for potential conserved region using an Immune Epitope Database and Analysis Resource (IEDB). This analysis shows that HLA-DRB1*0101, HLA-DRB3*0101, HLA-DRB1*0401, HLA-DRB1*0102 and HLA-DRB1*07:01% of class II (in genotype 2) and HLA-A*0101, HLA-A*02, HLA-A*0301, HLA-A*2402, HLA-B*0702 and HLA-B*4402% of HLA I (in genotype 3) bound peptides are conserved. The predicted peptides MHC class I are ILDSNGDIIGLY, FVMDEAHFTDPA, KTRKILPQIIK, RLMSPNRVPNYNLF, APTRVVAAEMAEAL, YENVFHTLW and MHC class II molecule are TTGVYRIMARGILGT, NYNLFVMDEAHFTDP, AAAIFMTATPPGTTD, GDTTTGVYRIMARGI and FGEVGAVSL found to be top ranking with potential super antigenic property by binding to all HLA. Out of these the predicted peptide FVMDEAHFTDPA for allele HLA-A*02:01 in MHC class I and NYNLFVMDEAHFTDP for allele HLA-DRB3*01:01 in MHC class II was observed to be most potent and can be further proposed as a significant vaccine in the process. The reported results revealed that the immune-informatics techniques implemented in the development of small size peptide is useful in the development of vaccines against the Japanese encephalitis virus (JEV).Entities:
Keywords: Epitope; Japanese encephalitis; MHC; Peptide; Vaccine
Year: 2016 PMID: 30581316 PMCID: PMC6302886 DOI: 10.1016/j.sjbs.2016.01.041
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 1319-562X Impact factor: 4.219
MHC-1 best alleles HLA-A*01:01, HLA-A*02:01, HLAA*03:01, HLAA*24:02, HLAB*07:02, HLA-B*44:02.
| S.I. | Alleles | Seq num | Start | End | Length | Peptide | Method | Percentile rank | Receptor | Energy |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. | HLA-A*01:01 | 1 | 139 | 150 | 12 | ILDSNGDIIGLY | ANN | 0.2 | NS3 | −597.74 |
| 3. | HLA-A*03:01 | 1 | 200 | 210 | 11 | KTRKILPQIIK | Consensus (ANN/SMM) | 0.2 | NS3 | −583.94 |
| 4. | HLA-A*24:02 | 1 | 269 | 282 | 14 | RLMSPNRVPNYNLF | ANN | 0.2 | NS3 | −519.28 |
| 5. | HLA-B*07:02 | 1 | 223 | 236 | 14 | APTRVVAAEMAEAL | ANN | 0.3 | NS3 | −509.21 |
| 6. | HLA-B*44:02 | 1 | 42 | 50 | 9 | YENVFHTLW | Consensus (ANN/SMM) | 0.15 | NS3 | −578.85 |
The bold value indicate best binding affinity and energy score.
Interacting amino acid of allele with NS3.
| S. No. | Allele | Interacting amino acid residues |
|---|---|---|
| 1. | HLA-A*01:01 | I1, L2, D3, S4, N5, G6, D7, I8, I9, G10, L11 and Y12 |
| 2. | HLA-A*02:01 | F1, V2, M3, D4, G5, A6, H7, F8, T9, D10, P11 and A12 |
| 3. | HLA-DRB3*01:01 | N1, Y2, N3, L4, F5, V6, M7, D8, E9, A10, H11, F12, T13, D14 and P15 |
| 4. | HLA-DRB1*04:01 | A1, A2, A3, I4, M6, T7, A8, T9, P10, P11, G12, P13, T14 and D15 |
MHC Class-II best alleles HLADRB1*0101, HLA-DRB3*0101, HLA-DRB1*04:01. HLA-DRB1*01:02, and HLA-DRB1*07:01.
| S.I. | Alleles | Start position | End position | Percentie rank | Predicted epitope | Length | Receptor | Energy |
|---|---|---|---|---|---|---|---|---|
| 1. | HLA-DRB1*01:01 | 19 | 33 | 3.95 | TTGVYRIMARGILGT | 14 | NS3 | −556.82 |
| 3. | HLA-DRB1*04:01 | 310 | 324 | 1.31 | AAAIFMTATPPGTTD | 14 | NS3 | −572.89 |
| 4. | HLA-DRB1*01:02 | 16 | 30 | 0.22 | GDTTTGVYRIMARGI | 14 | NS3 | −561.69 |
| 5. | HLA-DRB1*07:01 | 114 | 128 | 0.66 | FGEVGAVSL | 14 | NS3 | −483.12 |
Figure 1Showing the interaction of HLA-A*01:01 (in purple color) with NS3. The green dotted lines are showing the hydrogen bond. Graphics developed by Discovery Studio Visualizer 4.1.
Figure 2Showing the interaction of HLA-A*02:01 (in purple color) with NS3 .The green dotted lines are showing the hydrogen bond. Graphics developed by Discovery Studio Visualizer 4.1.
Figure 3Showing the interaction HLA-DRB3*01:01 (in purple color) with NS3. The green dotted lines are showing the hydrogen bond. Graphics developed by Discovery Studio Visualizer 4.1.
Figure 4Showing the interaction HLA-DRB1*04:01 (in purple color) with NS3.The green dotted lines are showing the hydrogen bond. Graphics developed by Discovery Studio Visualizer 4.1.